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To prospectively evaluate the prognostic significance of TP53, H-, K-, andN-Rasmutations, DNA-ploidy and S-phase fraction (SPF)
in patients affected by locally advanced laryngeal squamous cell carcinoma (LSCC). Eight-one patients (median follow-up was
71 months) who underwent resective surgery for primary operable locally advanced LSCC were analyzed. Tumor DNA was
screened for mutational analysis by PCR/SSCP and sequencing. DNA-ploidy and SPF were performed by flow cytometric analyses.
Thirty-six patients (44%) had, at least, a mutation in the TP53 gene. Of them, 22% (8/36) had double mutations and 3% (1/36) had
triplemutations. In total, 46TP53mutationswereobserved. Themajority (41%)of these occur in exon5 (19/46),while themutations
in exons 6, 7, and 8were represented in 14, 7, and 6 patients, respectively (31%, 15%, and 16%). Five LSCC patients (6%) showed a
mutation in H-Ras gene. Sixty-three percent of the cases (51/81) were DNA aneuploidy, 14% of these (7/51) were multiclonal.
Thirty-nine patients (48%) had an high SPF value. At Univariate analysis, theDNA aneuploidy, high SPF (>15.1%), TP53mutations
and, in particular, the mutations that occur in exons 5 and 8 were significantly related to quicker disease relapse and short OS. At
Multivariate analysis, the major significant predictors for both disease relapse and death were high SPF and any TP53 mutations.
While histological grade G3 was an independent factor only for relapse. In conclusions, any TP53 mutations and high SPF are
important biological indicators to predict the outcomeof LSCCpatients. J. Cell. Physiol. 206: 181–188, 2006. 2005Wiley-Liss, Inc.
The tumor of the larynx is a rare form of neoplasia
representing 2% of all human tumors. From 90% to 95%
of such cancers are laryngeal squamous cell carcinomas
(LSCC) (Rizos et al., 1999); incidence varies according to
geographical area and most probably depends on specific
environmental risk factors (Parkin et al., 1993). With
regard to their site of origin, LSCCs may show a variable
disease course and furthermore, tumors with exactly the
same clinical and histological features may have a
different clinical outcome. This indicates that tradi-
tional clinicopathological staging based only on the
TNM system and on histological grading may not be
sufficient for an accurate identification of patients at
high-risk for disease recurrence or death (Goldsmith
and Pillsbury, 1991; Tomasino et al., 1996). Published
data report that highly-proliferative tumors (high S-
phase fraction evaluated by flow cytometry) with
aneuploid DNA cell content are more aggressive (Merkel
and McGuire, 1990; Tomasino et al., 1995). Whereas, the
prognostic value of DNA ploidy has been clearly
established for other types of solid tumors (Ross, 1993),
its role in LSCCs is still controversial. Moreover, certain
molecular events leading to carcinogenesis of the larynx
are still not fully understood. Several protoncogens and
oncosuppressors would seem to be targets for risk
factors, for example, tobacco, excessive alcohol, expo-
sure to certain environmental carcinogens such as
asbestos, all commonly associated with the development
of LSCCs (Ronchetti et al., 2004). Until now, no well-
defined genetic model of LSCC progression has been
identified. However, it has been proposed a model where
genetic alterations of oncogens and oncosuppressors are
involved in the early phases, and in the promotion and
progression of laryngeal cancer (Califano et al., 2000).
Furthermore, it is probably the accumulation of such
genetic alterations and not necessarily their order,
which brings about progression. Nevertheless, muta-
tions of the oncosuppressor TP53 would seem to
represent an early event in the development of head
and neck cancers.
Several reports have shown that mutations of TP53
are present in about 50% of solid tumors, although the
frequency of such mutations varies according to the type
of tumor involved (Chang et al., 1993; Levine et al., 1994;
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Soussi et al., 1994). Data regarding the mutation rate in
LSCCs are discordant. In human tumors there is often
the loss of both TP53 alleles and whereas the first one
may show puntiform mutations, the second allele may
be lost during tumor progression. Most of the TP53
mutations have been found in exons 5–8; many of these
may lead to the formation of a protein able to alter its
bond with the DNA and which has a longer average life-
span resulting in cell accumulation.
Data regarding the frequency of mutations in genes of
the Ras family (H- K- N-Ras) in patients with LSCCs are
also discordant. Most of the mutations of these three
genes are found in codons 12 and 13, and some, but
fewer, in codon 61. In any case, mutations in these genes
always lead to the expression of a constitutionally active
proteic product.
Further information on the role of oncogene and
oncosuppressor alterations and their proteic products
might be useful for the identification of new factors
aimed at the diagnosis and treatment of LSCCs. The
aim of our study was to analyze in 81 cases of locally
advanced LSCCs, the mutational status of TP53 and
of the Ras family genes, by means of PCR-SSCP and
sequencing, the status of DNA ploidy and SPF, by means
flow cytometric technique, to establish their association
with traditional clinicopathological variables and to
determine their possible prognostic value.
MATERIALS AND METHODS
Study design
A prospective study was performed on paired tumor and
normal laryngeal tissue samples from a consecutive series of 81
patients of which 60 in stage III and 21 in stage IV undergoing
potentially radical surgical resection for primary tumor of
larynx at a single institution (Department of Oncology,
University of Palermo, Palermo, Italy) between April 1990
and December 1998. Briefly, the following inclusion criteria
were used: (a) electively resected primary LSCC, (b) processing
of fresh paired normal mucosa-tumor samples within 30 min
after tumor removal. In order to avoid evaluator variability in
the patients, all resection specimens and microscopic slides
were meticulously examined by two independent pathologists
(R.M.T. and V.M.) who were not aware of the original diagnosis
and of the results of the molecular analysis. The complete
excision of the primary tumor was histologically proven by
examination of the resected margins. All tumors were histo-
logically confirmed to be squamous cell carcinomas. In addi-
tion, the pathologists assessed tumor site (supraglottis, glottis,
subglottis), tumor size, pathological stage, tumor grade
(histological differentiation), and the presence or absence of
lymph node metastases. Tumors were staged according to the
American Joint Committee on Cancer (AJCC) and graded as
well (G1), moderately (G2), and poorly (G3) differentiated.
Lymph node involvement was evaluated clinically and histo-
logically without considering the number or location of nodes.
Written informed consent was obtained from all patients
included in this study. Information on survival (disease-free
survival—DFS—and overall survival—OS) was obtained
directly from clinical charts and through the Oncology Section
at our Institution. Clinicopathological, and research variables
and follow-up data of all patients have been recorded
prospectively in a computerized registry database.
Postoperatively, all patients were checked at 3-monthly
intervals for the first 2 years, at 6-monthly intervals for the
next 2 years, and annually thereafter. The follow-up program
included a clinical examination, blood tests (including CEA
and SCC assays), and annual chest X-ray. Disease relapse
(local recurrence or distant metastases) was confirmed histo-
logically where possible.
Tissue handling and DNA extraction
Multiple samples (4 to 8) of the primary tumor tissue were
taken from at least four different tumor areas (including the
core and the invasive edge of the tumor). The portion of primary
tumor was obtained by superficial biopsy of either the tumor
bulk or the edge of the malignant ulcer for more infiltrative
cancer. All tissues were carefully trimmed to remove as much
non-neoplastic tissue as possible, avoiding the non-viable
areas. Furthermore, samples of normal mucosa (as confirmed
by histology) were taken from a macroscopically uninvolved
area 2–5 cm away from the tumor site, to be used as control for
biomolecular and flow cytometric analysis. The tissues were
bisected, one-half of each sample was processed for pathologi-
cal examination, and the remaining half of the sample pool was
immediately frozen and stored at 808C until analyzed. The
adequacy of the material was checked on frozen tissue sections
and only tissue samples with more than 80% tumor content
were utilized in subsequent biomolecular and flow-cytometric
analyses. Where present, areas with a high content of non-
neoplastic cells were removed from the frozen block with a
scalpel. Evaluation of each biomolecular variable (genetic
status of TP53 and H- K- N-Ras, DNA-ploidy, and S-phase
fraction) was performed independently by researchers who
had no knowledge of the clinical data regarding the samples.
Genomic DNA was extracted using the QIAamp Tissue Kit
(Qiagen, Hilden, Germany) with the standard protocol from
primary LSCC and normal laryngeal specimens.
Detection of TP53 and H- K- N-Ras
gene mutations
Mutations within the H- K- N-Ras and TP53 genes were
detected by SSCP analysis following PCR amplification of the
exon 1 for H- K-Ras, exons 1–2 for N-Ras, and of the exons 5–
8 for TP53, respectively (Table 1), performed as previously
described (Bazan et al., 2002a; Russo et al., 2002) controls were
amplified by PCR and included in the experiment. In all PCR
assays, aerosol-resistant pipette tips were used to avoid cross-
contamination. The quality and the concentration of the
amplification products were verified by 1.5% agarose gel
electrophoresis and ethidium bromide staining. One-hundred
nanogram aliquots of the amplified DNA fragments, purified
and concentrated by filtration through Microcon 50 columns
(Amicon, Beverly, MA) were denatured and analyzed by
SSCP analysis. PCR-SSCP analysis was repeated twice for
each sample to minimize the possibility of artifacts due to
TABLE 1. PCR primers used for PCR and SSCP analyses of p53, H-, K-, N-Ras genes
Primers: sense 50 ! 30 Primers: antisense 50 ! 30 Anneal, 8C
P53
Exon 5 TTCCTCTTCCTACAGTAGTC CGATGGTGAGCAGCTGGG 588
Exon 6 CGATGGTGAGCAGCTGGG ATGGCAAAACCAGACCTCAG 508
Exon 7 TGTGTTATCTCCTAGGTTGG TGGCAAGTGGCTCCTGAC 58
Exon 8 TCCTATCCTGAGTAGTGGT TCCTGCTTGCTTACCTCG 548
H-Ras
Exon 1 GACGGAATATAAGCTGGTGG TAACTACCCCTCTGCACGGA 588
K-Ras
Exon 1 GTGTGACATGTTCTAATA-
TAGTGACA
GAATGGTCCTGCACCAGTAA 588
N-Ras
Exon 1 GACTGAGTACAAACTGGTGG CTCTATGGTGGGATCATATT 548
Exon 2 GGTGAAACCTGTTTGTTGGA ATACACAGAGGAAGCCTTCG 548
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contamination or polymerase errors and interpretation of
SSCP analysis was performed by consensus of two investiga-
tors. DNA of normal mucosa from each patient was also
amplified and run in parallel with matched tumoral DNA
samples on SSCP gels, to evaluate the occurrence of germ line
mutations or polymorphisms. Individual ssDNA fragments
with shifted mobilities, compared to normal control, were
electroeluted from polyacrylamide gel, as described previously
(La Farina et al., 1998), reamplified and sequenced. Automated
sequencing was performed using the Big Dye Terminator Cycle
Sequencing Kit (Applied Biosystem, Foster City, CA) and the
model 3100A Genetic Analyzer (Applied Biosystem).
Cellular DNA content and S-phase fraction (SPF)
flow cytometric analyses
DNA flow cytometry was performed on mechanically
disaggregated samples of frozen tumor tissue to determine
DNA-ploidy, DNA index, and S-phase fraction (SPF) as pre-
viously reported (Russo et al., 1994). Briefly, healthy laryngeal
mucosa was used as an internal DNA-diploid control for each
sample. Tumors with DI¼ 1 were defined as DNA-diploid and
those with lower or higher DI values were considered DNA-
aneuploid if they contained >10% aneuploid cells. DNA
aneuploidy results were further subdivided into monoploid
(with only one aneuploid peak) and multiploid (with two or
more aneuploid peaks).
Statistical analysis
Association between biological and clinicopathological vari-
ables was evaluated by means of the Chi-square test and,
where appropriate, Yates’ correction. DFS was measured from
the day of primary surgery to the date of first relapse
(locoregional or metastatic) and OS from the day of surgery
to the day of death specifically due to the LSCC. If patients did
not relapse or die, they were censored at the time of their last
follow-up. Clinical and morphobiological variables were exam-
ined by means of the Kaplan–Meier method; significance of
differences for each prognostic factor was assessed by the log-
rank and Wilcoxon tests or trend tests, where appropriate.
Multivariate analysis was carried out by means of Cox pro-
portional hazards model, using a backward procedure (Cox,
1972). P values less than 0.05 were considered statistically
significant.
RESULTS
Clinicopathologic variables
The majority (98%) of patients affect by locally ad-
vanced LSCC are males (79/81) while only 2% of patients
are female (2/81) (Table 2). Sixteen patients (20%) are
less than 60 years old, 40 (49%) of them are from 60 to
69 years old, while 25 (31%) are more than 69. The
median age is 66 years (range 44–85). Forty-eight
patients (59%) showed a tumor in glottis, 29/81 (36%)
in supraglottis, and 4/81 (5%) in subglottis. Twenty-four
patients (30%) had a stage IV tumor while, the others,
57 patients (70%) have a stage III tumors. In addition,
these series included 60 (74%) tumors limited to the
larynx with vocal cord fixation while 21 (26%) have an
extension beyond confines of larynx. Assessment of the
grade of differentiation of the tumor showed that there
were 20/81 (25%) well- (G1), 47/81 (58%) moderately-
(G2), and 14/81 (17%) poorly-differentiated LSCC. Node
status was known for all patients, with 21/81 (26%)
being node positive and 60/81 (74%) being node negative.
Mutation analysis of the
Ras genes family (H- K- N-Ras)
Mutation analysis of exon 1 of the H- K-Ras genes and
exons 1–2 of N-Ras gene were performed on genomic
DNA from locally advanced LSCC of 81 patients by the
PCR-SSCP technique. Aberrantly migrating bands
were found in 6% (5/81) of the cases. All samples have
mutations in H-Ras gene. Unfortunately, it was not
possible to establish the exact site and nature of the
genetic alterations in 5 of the 81 patients because the
frozen material and mutated DNA were no longer
available. No other mutation was found in the other
genes of Ras family (N-, K-Ras).
Mutation analysis of the TP53 gene
Mutation analysis of exons 5 to 8 of theTP53 gene was
performed on genomic DNA from locally advanced LSCC
of 81 patients by the PCR-SSCP technique. Aberrantly
migrating bands were found in 44% (36/81) of the cases
(Fig. 1). Sequence analysis of the DNA fragments with
altered electrophoretic mobility made it possible to
establish the exact site and nature of the genetic altera-
tion in 18 tumor samples. Overall, 46 TP53 mutations
were identified in 36 of the 81 screened LSCCs, and
sequence data were obtained for 21. The features of the
TP53 mutations are summarized in Table 3. Of the 46
mutations, 41% (19 of 46) were in exon 5, 31% (14 of 46)
in exon 6, 15% (7 of 46) in exon 7, and 13% (6 of 46) in exon
8. Nine tumor samples were found to harbor two (eight
in two exons) or three (one in three exons) different TP53
mutations. Three of the 21 sequenced mutations (14%)
were found to be frameshifts (2 microdeletions and
1 microinsertions), whereas 18 (86%) were single-
nucleotide substitutions. Sixty-one percent of the latter
were missense (11 of 18), 39 were silent (7 of 18) muta-
tions, while were not found any nonsense mutations.
Moreover, transitions (61%, 11 of 18) were far more
frequent than transversions (31%, 7 of 18). The 21
mutations identified spanned 14 codons, interesting all
of the TP53 mutations in exon 6 occur in codon 213. No
germ line mutations were found indicating that in every
case the change was somatic. Twenty-nine percent of the
mutations (6 of 21) occurred in conserved domains
(areas II–V). In addition, by taking into account the
specific functional and structural domains of TP53
affected by the mutations, the mutations were classified
as follows: 2/21 cases (9%) with mutations of the L2, 3/21
cases (14%) with mutations of the LSH motif, and 1/21
cases (5%) with mutations of the L3. Since silent
mutations do not determine any aminoacid change in
the protein, they have been included in wild-type group
for statistical analysis.
TABLE 2. Patient characteristics (n¼ 1)
No. of patients
Sex
Male 79
Female 2
Age (yr)
<60 16
60–69 40
70 25
Tumor site
Supraglottis 29
Glottis 48
Subglottis 4
Node status
Negative 60
Positive 21
Size
T3 60
T4 21
Stage
III 57
IV 24
Tumor grade
G1 20
G2 47
G3 14
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Cellular DNA content and S-phase evaluation
Adequate DNA histograms were obtained for all
normal and tumoral tissues by means of flow cytometry.
The coefficients of variation of the DNA-diploid peaks
ranged from 2.5% to 4.8% (median 3.4%). DNA aneu-
ploidy was found in 63% of the cases (51/81), and 14% of
these (7/51) showed multiclonality. The SPF ranged
from 3.2% to 38% (median: 15.1% and interquartile
range: 7.1%–20.6%). The median SPF of DNA-aneu-
ploid tumors was 18.6% while that of the DNA-diploid
tumors was 6.8% (P< 0.01). By using the SPF median
value as cut-off point, tumors were accordingly divided
into low (¼15.1) and high (>15.1) SPF tumors.
Relationship between biomolecular
indicators and clinical data
No significant relationship was seen between the
clinicopathological and biological variables analyzed
(data not shown).
General outcome
The median follow-up time in our study group was
71 months (range 11–137 months). At the time of this
report, 45/81 patients had relapsed, of which 33 had
distant metastases and 12 locoregional recurrence,
while 41/81 had died for tumor related causes. The
median survival of the whole group was 69 months and
the survival at 5 years was 52.8%.
Uni- and Multivariate analysis of
prognostic factors
At univariate analysis, presence of lymph node
metastases, tumor grade G3, DNA-aneuploidy, high
SPF (>15.1%), any TP53 mutations (Table 4), and the
type of TP53 mutations (mutations in exon 5 vs.
mutations in exons 6–8 or mutations in exon 8 vs.
mutations in exons 5–7) (data not shown) proved to be
significantly related to quicker relapse and shorter
overall survival. Figure 2 shows the probability of DFS
(a) and OS (b) according to TP53 mutations. The limited
number of cases mutated in H-Ras, does not permit to
enclose a statistical analysis. The significant variables
at univariate analysis were entered in a multivariate
logistic regression model with backward elimination. At
multivariate analysis, high S-phase and any TP53
mutations were independent prognostic factors, both
for disease recurrence and for survival, while advanced
histological grade was only predictive of the former
(Table 5). Furthermore, when only exon 5 mutations and
not any TP53 mutations were considered, they proved to
be prognostically independent variable both for disease
Fig. 1. SSCP analysis of exon 8 of the p53 gene amplified from
laryngeal squamous cell carcinomas (LSCC) and normal-appearing
tissue genomic DNA of one patient (case 827). The tumor DNA is at the
left (T) and the normal tissue DNA (N) is at the right (a). The extra
bands visualized by arrows in line 2 correspond to ssDNA molecules
harboring mutations in codon 282 (CGG to TGG) as confirmed by
sequencing (b).
TABLE 3. List of 21 p53 characterized mutations in 18 patients with LSCCs
Sample Mutated exon Mutated codon
Nucleotide
change
Aminoacid
change Type mutation CD Zn-BD
261 5 159–160 GCCATG!GTG — Frameshift N —
335 6 213 CGA!CGG Arg!A0rg Missense N —
383 7 248 CGG!TGG Arg!Trp Missense Y L3
402 7 278 GAA!GCAA — Frameshift Y LSH
419 5 179 CAT!TAT His!Tyr Missense Y L2
484 5 151 CCC!CT — Frameshift N —
6 213 CGA!CGG Arg!Arg Missense N —
511 5 157 GTC!TTC Val!Phe Missense N —
671 7 265 GGC!TGC Gly!Cys Missense N —
765 6 213 CGA!CGG Arg!Arg Missense N —
788 5 184 GAT!AAT Asp!Asn Missense N L2
6 213 CGA!CGG Arg!Arg Missense N —
798 6 213 CGA!CGG Arg!Arg Missense N —
827 8 282 CGG!TGG Arg!Trp Missense Y LSH
829 5 137 CTG!CAG Leu!Gln Missense Y —
832 5 151 CCC!CAC Pro!His Missense N —
7 249 AGG!ACG Arg!Thr Missense N —
840 7 245 GGC!TGC Gly!Cys Missense N —
993 8 280 AGA!ACA Arg!Thr Missense Y LSH
1027 6 213 CGA!CGG Arg!Arg Missense N —
1036 6 213 CGA!CGG Arg!Arg Missense N —
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TABLE 4. DFS and OS of the LSCCs patient according to clinicopathologic variables
DFS OS
No. of patients OR (95% CI) P No. of patients OR (95% CI) P
Total ptatiens 81 81
Tumor grade
G1 20 1.00 20 1.00
G2 47 2.07 (0.90–4.75) n.s. 47 1.91 (0.83–4.41) n.s.
G3 14 3.70 (1.40–9.79) 0.008 14 2.58 (0.93–7.13) 0.068
Node status
Negative 60 1.00 60 1.00
Positive 21 2.8 2 (1.41–5.64) 0.003 21 2.57 (1.25–5.27) 0.018
DNA-ploidy statusa
Diploid 30 1.00 30 1.00
Aneuploid monoclonal 44 3.18 (1.54–6.56) 0.002 44 2.6 0 (1.25–5.43) 0.011
Aneuploid multiclonal 7 5.47 (1.97–15.3) 0.003 7 4.07 (1.37–12.1) 0.011
SPFb
15.1% 40 1.00 40 1.00
>15.1% 39 3.8 0 (1.99–7.26) <0.001 39 2.88 (1.49–5.57) 0.002
p53c
No mutations 45 1.00 45 1.00
Any mutations 36 2.11 (1.16–3.83) 0.014 36 2.75 (1.45–5.21) 0.002
aAll DNA-aneuploid subgroups are compared with patients with DNA-diploid tumors.
bAll high SPF subgroups are compared with patients with low SPF tumors.
cAll mutation subgroups are compared with patients with no mutations (wild-type p53).
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Fig. 2. DFS (a) and OS (b) of 81 patients with LSCC according to p53 mutations.
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recurrence and for survival, while exon 8 mutations
were only predictive of the latter (data not shown).
DISCUSSION
The classification of epithelial hyperplastic lesions of
the larynx is based, principally, on the progression of
their histological features to LSCC. Although so far
there has been no clear definition of a genetic model for
LSCC progression, it would appear that it depends on
an accumulation of genetic alterations (Califano et al.,
1996). The most frequent events regard alterations of
the gene TP53, which seem to be present in the early
phase of the development of LSCCs. Several studies
have reported that TP53 mutations bring about the loss
of normal protein function, resulting in genomic instabi-
lity and the occurrence of gross genomic abnormalities
(Dowell and Hall, 1995; Ko and Prives, 1996; Levine,
1997; Lane, 1999; Prives and Hall, 1999; Somasun-
daram, 2000). Since TP53 mutations are an early event,
therefore, further genomic alterations are necessary for
the progression of the hyperplastic lesion into a clear
carcinoma.
Previous analyses performed by several researchers
on different types of tumors have shown that most of
the TP53 mutations affect exons 5–8, which code for
residues 130–286, the most important region for the
folding and the stabilization of the tertiary structure of
the protein, and which contains the site-specific, DNA-
binding domain (Cho et al., 1994). Mutations outside
exons 5–8 are rarely found and include mutations oc-
curring within the introns of the splicing sites, which
appear to bring about aberrant RNA splicing. In this
study, performed on 81 patients with locally advanced
LSCCs, we found a mutation rate of 57% (46/81), which
is higher than that reported in literature for LSCCs at
the same stage (30%–50%) (Li, 1995; Sarkar et al., 1996;
Golusinski et al., 1997; Alsner et al., 2001). Several
factors might be responsible for this variability, for
example, the presence of silent mutations, the hetero-
geneity of tumors and also the different methods used
for identifying the mutations and for storing samples.
There is no doubt that disease stage is an important
factor with regard to the TP53 mutation rate. Several
reports, in fact, have shown that TP53 mutations have
been found in early lesions and that their frequency
appears to increase in carcinomas at more advanced
stages (Dolcetti et al., 1992; Maestro et al., 1992; Anwar
et al., 1993a; Boag et al., 1993; Boyle et al., 1993; Chung
et al., 1993; Field et al., 1993; Nadal and Cardesa, 2003).
Nine tumor samples were found to harbor more than one
TP53 mutations; for our experience, it may establish
that these mutations origins from a multiclonal tumor
but only the use of more accurate techniques, such us
Laser Microdissection, may throw light upon this
investigation (Bazan et al., 2005).
Several studies have reported that the TP53 exons
most commonly mutated depend on the geographical
area involved. In the USA, in fact, such mutations
usually regard exon 7 (Brachman et al., 1992), in Japan,
exons 5 and 8 (Sakai and Tsuchida, 1992), and in the
United Kingdom exon 4 (Field et al., 1993). In our own
study most of the mutations occurred in exon 5. Even if
the number of cases presented in this study is limited,
we propose that environmental factors could be funda-
mental in the development of larynx tumors. The
presence of different mutations might depend on specific
local carcinogens, which possibly interact with more
common factors, such as alcohol and tobacco, predispos-
ing to a multistep process that leads to epithelial larynx
tumorigenesis.
Furthermore, it seems that the Ras family genes play
an exceptional part in laryngeal carcinogenesis. Al-
though literature has reported a high mutational rate in
laryngeal carcinoma (Anwar et al., 1993b), such results
have not been confirmed for LSCCs (Fracchiolla et al.,
1995; Rizos et al., 1999). In our own cases of locally
advance LSCCs, we found a mutational rate of 6% (5/81)
in the gene H-Ras and none at all in K- and N-Ras. These
results agree with those of previous studies reporting a
low mutational rate in squamous cell carcinomas of the
head and neck (SCCHN) of subjects of the Western world
(Fracchiolla et al., 1995; Kiaris and Spandidos, 1995;
Rizos et al., 1999). The difference in Ras gene mutations
in the various studies may be due to geographical
differences, which might modify the effect of exposure to
specific environmental risk factors (Fracchiolla et al.,
1995; Rizos et al., 1999). Our results, therefore, have
confirmed that the Ras oncogens do not seem to be
implicated in the carcinogenesis of LSCCs. On the other
hand, it appears that in such tumors the main activation
mechanism of Ras genes is their aberrant expression,
which probably depends not on mutations of the first
codifying exon, but on alterations of the gene promoter,
an instability of the Ras gene chromosome carriers
resulting in genic amplification (McDonald et al., 1994;
Kiaris et al., 1995).
Furthermore, although DNA-ploidy and SPF evalu-
ated by flow cytometry, continue to be used in many
types of tumors for the prediction of the clinical outcome
of the disease, their function has still not been clearly
defined in cases of LSCCs.
The difference in published reports might depend on
sampling and storing methods (fresh, frozen, paraffin-
embedded). In our own study, although DNA aneuploidy
and high S-phase did not prove to be linked to any of
the clinicopathological and biological variables exam-
ined, it may well be that the genomic instability caused
by the alteration or loss of function of TP53 gave rise
to a selection of highly proliferative aneuploid clones.
In advanced tumors, the accumulation of alterations in
TABLE 5. Cox proportional hazards analysis to predict the HR of relapse or death in LSCC patients
Relapse (N¼ 81) Death (N¼ 81)
HR (95% CI) P HR (95% CI) P
Tumor grade
G3 versus G1 3.56 (1.33–9.55) 0.011
SPF
>15.1% versus 15.1% 4.00 (2.07–7.73) <0.001 3.10 (1.58–6.10) 0.001
p53
Any mutation versus no
mutation
2.07 (1.11–3.85) 0.023 3.05 (1.57–5.91) <0.001
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the oncogens, oncosuppressors, and genes involved in
the maintenance of genomic integrity might make the
tumoral mass deriving from such clones particularly
resistant to treatment, resulting in a worse clinical
outcome. (Russo et al., 1995).
Although TP53 gene alterations are commonly found
in head and neck cancers, their prognostic value in
LSCCs has not been clearly established. Our report
showed that any TP53 mutations and high SPF are
strong prognostic indicators of both disease recurrence
and survival in patients with locally advanced LSCCs.
These findings also show thatTP53 gene status and SPF
maintain their predictive role even the presence of
established traditional prognostic variables such as
tumor site, node status, size, and histological grade.
Our investigation confirms and reinforce previous
studies on the prognostic role of TP53 alterations and
high SPF. Some studies in fact showed that TP53
overexpression is an independent prognostic factor for
disease-free and overall survival in primary and ad-
vanced LSCCs (Hirvikoski et al., 1997; Jin et al., 1998;
Jackel et al., 2001). Moreover some studies identified
high SPF as an important biological indicator in LSCCs
(Tomasino et al., 1995). Although it is not yet clear how
the evaluation of the TP53 mutation status associated or
not with cell proliferation should be inserted in the
choice of theraupetic management of locally advanced
LSCCs these biological indicators might provide infor-
mation and rational basis to develop more specific
clinical treatment for this group of patients.
It may well be that not all TP53 mutations are func-
tionally equal. Such mutations, in fact, might be divided
into two groups. The first involves the mutations respon-
sible for structural anomalies, which might destabilize
the tertiary structure of the protein and bring about
loss of binding capacity to DNA. The second group
regards mutations leading to an alteration of amino acid
residues, which interact with the DNA, eliminating
crucial contact with the latter (Iniesta et al., 1998).
Depending on the location of a TP53 mutation, there-
fore, the suppressive functions or clinical outcome may
or may not be affected (Chomchai et al., 1999). Some
alterations could lead to a nuclear p53 protein accumu-
lation detected by immunohistochemistry (IHC); some
mutations could lead to the production of a truncated
protein, or to a protein with a C-terminal aminoacid
sequence very different from that of the wild-type, may
not cause its stabilization and consequent accumulation
(Bazan et al., 2002b).
For these reasons, IHC and mutational analysis of p53
appear to be complementary rather than equivalent
methods of investigation to assess the occurrence of
alterations in this key regulator of cell proliferation,
genetic stability, and apoptosis.
In conclusion, in our study it has been observed a
strong association between TP53 mutations and an
unfavorable prognosis, both with regard to higher risk of
disease recurrence and to death, in patients affected by
locally advanced LSCCs. If our results are confirmed by
large prospective studies, it will be possible to considere
such patients as suitable candidates for alternative
treatment strategies directed against tumors with
mutated TP53.
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